AVO.L Regulatory News (AVO)

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Confirmation of board appointments

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that, further to the Company's announcement of 2 July 2018, Dr. Peter Sjostrand, Mr. Gabriel Urwitz, Mr. Chunlin Han, Mrs. RenHua Zhang and Dr Yuelong Huang have been appointed as Non-Executive Directors, with immediate effect.

Information required by Rule 17 and Schedule Two paragraph (g) of the AIM Rules are disclosed below:

Peter Sjostrand - Non-Executive Director & Vice-Chairman

Peter Sigurd Ivar Sjostrand, aged 72, owns no shares in the Company. Mr Sjostrand has a long career as an independent Non-Executive Director for a number of public and private companies within the Healthcare, Industrial and Financial areas. He has been a director of the following companies during the previous five years:

Gabriel Urwitz - Non-Executive Director

Bo Gabriel Urwitz, aged 68, has an extensive background in industry and finance and has been involved with a large number of successful listed and private companies during his career. Gabriel co-founded Segulah Advisors AB in 1994 and was adjunct professor of financial economics at the Stockholm School of Economics from 1977 until 2002. Mr Urwitz is a Director of AB Segulah, which owns 3.84% of the Company. A consortium led by AB Segulah owns 8.03%. Mr Urwitz has been a director of the following companies during the previous five years:

Mr Urwitz is a deputy member of the board of GridZupport Sweden AB which began bankruptcy proceedings on 12 December 2017; on 27 May 2018 the assets and liabilities of GridZupport were acquired by Segulah Venture AB.

Mr Urwitz was a director of Gota Bank, resigning in August 1992. The holding company of Gota Bank, Gota AB, was declared bankrupt in September 1992.

Mr Urwitz was also a member of the board of Segulah Norway Investment AB when it entered into liquidation on 15 September 2017.

Mr. Chunlin Han - Non-Executive Director

Representing Liquid Harmony Ltd which owns 29.9% of the Company, Chunlin Han, aged 25, is a Director of Hangzhou Ruilin Ynovo Investment Partners Ltd. which wholly owns Liquid Harmony Limited. Mr Han is an executive Director of Liquid Harmony Ltd and serves as Head of Investment and Financing for Realcan Pharmaceuticals Co. Ltd. Mr Han has been a director of the following companies during the previous five years:

Mrs. RenHua Zhang - Non-Executive Director

Representing Liquid Harmony Ltd which owns 29.9% of the Company, RenHua Zhang, aged 52, owns no shares in the Company although is considered to be acting in concert with Liquid Harmony Ltd. Mrs Zhang is the co-Founder, CEO, and Vice Chairman of the board of Realcan Pharmaceutical Co. Ltd, a large distributor of medical drugs and equipment in China with access to more than 8,000 hospitals. Mrs Zhang has been a director of the following companies during the previous five years:

Dr Yuelong Huang - Non-Executive Director

Representing Liquid Harmony Ltd which owns 29.9% of the Company, Yuelong Huang, aged 41 owns no shares in the Company although is considered to be acting in concert with Liquid Harmony Ltd. Scientist by background, Mr Huang serves as General Manager of Medical Technology Department of Realcan Pharmaceuticals Co. Ltd where he is responsible for all M&A activities and medtech R&D/manufacturing. Mr Huang has been a director of the following companies during the previous five years:

Save as set out in this announcement, there are no further details to be disclosed under Rule 17 or Schedule 2(g) of the AIM Rules for Companies in respect of the appointments set out above.

For further information, please contact:

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.